Correction to: Metformin inhibits cardiometabolic syndrome associated cognitive deficits in high fat diet rats (Journal of Diabetes & Metabolic Disorders, (2022), 21, 2, (1415-1426), 10.1007/s40200-022-01074-4)

• Published in: Journal of Diabetes and Metabolic Disorders
• Main Author: Chellammal H.S.J.; Hasan M.H.; Kshirsagar R.P.; Musukula V.K.R.; Ramachandran D.; Diwan P.V.
• Format: Erratum
• Language: English
• Published: Springer Science and Business Media Deutschland GmbH 2023
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165578702&doi=10.1007%2fs40200-023-01229-x&partnerID=40&md5=2a6d1535d4dc6f0c6d65989e3781af37

In the original publication of the article, the table 2 was incorrectly processed. The corrected Table 2 is provided below. The original article has been corrected. (Table presented.) Effect of metformin on glucose, insulin and lipid profile Group Glucose (mg/dl) Insulin (µg/L) HOMA-IR AUC (h.mg/l) Cholesterol (mg/dl) Triglycerides (mg/dl) HDL (mg/dl) LDL (mg/dl) I (Control) 93.68 ± 4.21 18.74 ± 0.70 4.31 ± 0.16 241.30 ± 3.59 87.60 ± 5.05 98.24 ± 5.96 44.33 ± 2.97 38.01 ± 3.08 II (HS) 364.50 ± 33.40a 12.52 ± 0.54a 11.24 ± 1.29a 342.60 ± 3.47a 122.30 ± 2.11a 178.10 ± 7.44a 26.61 ± 2.03a 97.13 ± 4.12a III (HS+Met 180mg) 179.30 ± 21.91e 14.46 ± 0.46 6.32 ± 0.63e 265.70 ± 1.88e 93.93 ± 5.11d 115.90 ± 6.25e 37.67 ± 2.87c 58.86 ± 6.33e V (HS+Met 360mg) 106.30 ± 7.65e 16.39 ± 0.56e 4.27 ± 0.28e 252.20 ± 2.78e 92.15 ± 7.11d 101.80 ± 6.67e 46.40 ± 2.59e 41.16 ± 4.44e Values are expressed as mean ± SEM of 6 animals. Superscript letters represent the statistical significance performed by ANOVA, followed by Tukey’s multiple comparison tests. ap < 0.001 indicates the comparison of Group II with Group I. cp < 0.05, dp < 0.01 and ep < 0.001, indicates the significance on comparing group III or IV with group II. (HS- high fat-high sucrose and Streptozotocin, Met- Metformin). © 2023, The Author(s), under exclusive licence to Tehran University of Medical Sciences.